NCT03880968 (T2TEAS) is a clinical trial of tapering or discontinuation of etanercept in Spondylitis, Ankylosing, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who is sponsoring NCT03880968?

NCT03880968 is sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University.

What drugs are being tested in NCT03880968?

Interventions in NCT03880968: tapering or discontinuation of etanercept.

What condition does NCT03880968 study?

NCT03880968 studies Spondylitis, Ankylosing.

Is NCT03880968 still recruiting?

NCT03880968 is currently completed. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT03880968: T2TEAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis

Completed Last updated 1 July 2021

What this trial tests

trial testing tapering or discontinuation of etanercept in Spondylitis, Ankylosing in 311 participants. Completed in 30 September 2014.

Timeline

1 March 2012

Primary endpoint
30 September 2014

30 September 2014

Quick facts

Lead sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	311
Start date	1 March 2012
Primary completion	30 September 2014
Estimated completion	30 September 2014

Drugs / interventions tested

tapering or discontinuation of etanercept — full drug profile →

Conditions studied

Spondylitis, Ankylosing — all drugs for Spondylitis, Ankylosing →

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Who can join

Adults 18 to 65, any sex, with Spondylitis, Ankylosing. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the disease activity guided tapering and discontinuation strategies of etanercept (ETN) in patients with ankylosing spondylitis (AS) in 48 weeks.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study.
Zhang T, Zhu J, He D, Chen X, et al · · 2020 · cited 8× · PMID 32536984 · DOI 10.1177/1759720x20929441

Verify or expand the search:

Other recruiting trials for Spondylitis, Ankylosing

Currently open trials in the same condition.

NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT05879419 — Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases · Phase 4 · active not recruiting
NCT05647577 — The Relationship Between Inflammatory ARTritis and CArdiac DIseAse · active not recruiting
NCT04731831 — Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response. · recruiting
NCT01422694 — Natural History and Development of Spondyloarthritis · recruiting

Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials

Trials by the same sponsor.

NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03880968 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03880968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing